In the subgroup with psychosis, we found suggestive evidence that CYP2D6 poor metabolisers were prescribed lower average antipsychotic doses compared to the normal metabolisers by almost 10 percentage points as a proportion of the maximum licensed dose according to the British National Formulary (BNF) guidelines (Figure 6). The gene discussed is CYP2D6; the disease is psychotic disorder.